Leonardo Roever: CHR as a Composite Biomarker for Stroke Risk Stratification
Leonardo Roever, CEO of Brazilian Evidence-Based Health Network, shared on LinkedIn about a recent article by Wei Huang et al, published in Lipids in Health and Disease:
”Association of C-reactive protein/HDL cholesterol ratio with stroke in Chinese adults with different glycemic levels
Stroke is one of the major public health problems in China, highlighting the need for accessible biomarkers to aid in risk stratification.
The C-reactive protein/HDL cholesterol (CHR) ratio, which integrates inflammatory and lipid pathways, has emerged as a new composite biomarker.
Higher CHR levels were associated with an increased risk of stroke in Chinese adults, with heterogeneity between different glycemic levels, showing stronger and nonlinear (J-shaped) associations in individuals with normal blood glucose than in individuals with diabetes.
CHR has demonstrated limited discriminatory ability for stroke, suggesting that its usefulness may lie in risk stratification rather than isolated prediction.
Follow me for more content on evidence, management, and innovation in health
Enroll now in the courses offered by the Brazilian Evidence-Based Health Network and take your research and scientific knowledge to the next level.”
Title: Association of C-reactive protein/high-density lipoprotein cholesterol ratio with stroke in Chinese adults across different glycemic status
Authors: Wei Huang, Jun Gu, Xueli Sun, Zhimei Shen, Qin Yin, Xu Wang
Read the Full Article on BMC/Lipids in Health and Disease
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 21, 2026, 12:08Amy Allen Whitfield: Helping to Proceed Bleeding Disorders Care
-
Aug 21, 2026, 11:53Jan Terje Andersen: Harnessing Placental Biology for Therapeutic Engineering
-
Aug 21, 2026, 11:02Severe ITP, Critical Bleeding, and the Challenge of Platelet Testing – RPTH Journal
-
Aug 21, 2026, 10:46Arwa Z. Al-Riyami: Looking Ahead to ISBT Muscat 2029
-
Aug 21, 2026, 10:42Janine Mothershed: What Is Romiplostim and How Does It Work in Immune Thrombocytopenia?
-
Aug 21, 2026, 10:33Omar Alkharabsheh: Excited to Build the Future of Hematologic Malignancy Care in Central Florida
-
Aug 21, 2026, 10:23Salvador Payán Pernía: Tailoring Therapy in Sickle Cell Disease – Mitapivat and the Path Toward Personalized Combination Care
-
Aug 21, 2026, 10:10Pete Stibbs: The Evolving Landscape of VTE Management
-
Aug 21, 2026, 09:58Nishant K Mishra։ When Epilepsy Meets Anticoagulation